Search research articles
Contact Us
Filters
Showing results (171-180 of 218) with videos related to
Page
of 22
Sort By:
Journal of the National Cancer Institute
|
October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis
Xavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
International Journal of Cancer
|
November 22, 2021
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3)
Markus Moehler, Gunnar Folprecht, Volker Heinemann, et al.
United European Gastroenterology Journal
|
March 28, 2020
Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research
Friederike Weise, Michael Vieth, Dirk Reinhold, et al.
International Journal of Cancer
|
July 26, 2021
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)
Arndt Stahler, Volker Heinemann, Julian Walter Holch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2020
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Elisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
Markus Moehler, Hong Xiao, Steven I Blum, et al.
Nature Medicine
|
March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
Kohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
BMC Cancer
|
September 2, 2016
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Markus Moehler, Irina Gepfner-Tuma, Annett Maderer, et al.
International Journal of Cancer
|
August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 218) with videos related to
Sort By:
Page
of 22
Journal of the National Cancer Institute
|
October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis
Xavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
International Journal of Cancer
|
November 22, 2021
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3)
Markus Moehler, Gunnar Folprecht, Volker Heinemann, et al.
United European Gastroenterology Journal
|
March 28, 2020
Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research
Friederike Weise, Michael Vieth, Dirk Reinhold, et al.
International Journal of Cancer
|
July 26, 2021
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)
Arndt Stahler, Volker Heinemann, Julian Walter Holch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2020
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Elisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
Markus Moehler, Hong Xiao, Steven I Blum, et al.
Nature Medicine
|
March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
Kohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
BMC Cancer
|
September 2, 2016
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Markus Moehler, Irina Gepfner-Tuma, Annett Maderer, et al.
International Journal of Cancer
|
August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
Page
of 22